الفهرس Only 14 pages are availabe for public view
 |  | from | 224 |  |  |
| | | from | 224 | | |
Abstract
Hepatitis C virus is a major cause of chronic liver disease, infecting 200 million persons worldwide
In Egypt high HCV rates were reported among several population groups reaching up to 20%
Interferon is an effective treatment for chronic hepatitis C, it is an immunomodulatory drug. Ribavirin is a nucleoside analogue, with a broad spectrum of activity against a variety of DNA and RNA viruses. At present, combination therapy with interferon alpha and ribavirin is considered the treatment of choice
Aim of work is to retrospectively study & compare between patients with chronic hepatitis C who had received standard interferon plus ribavirin and patients who had received pegylated interferon plus ribavirin regarding evaluation of the efficacy & the Predictors of response to the proposed treatment.
The study was conducted on 100 patients suffering from chronic hepatitis C who where previously diagnosed and treated in EL-Agouza Police Authority Hospital. These patients were divided into two groups. Group I, comprised 50 patients received standard interferon alpha (3M.I.U) 3 times weekly subcutaneously plus oral ribavirin in a dose ranging from 800-1200 mg/day. Group II, comprised 50 patients received pegylated interferon alfa-2a (180mcg/week) subcutaneously plus oral ribavirin in a dose ranging from 800-1200 mg/day.